van den Eertwegh, Alfonsus J M <br/><br/>
Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.  [electronic resource] 

 -  Urology  Jan 2013 
 - 143-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-9995 
<br/><br/><label>Standard No.: </label>10.1016/j.urology.2012.09.019  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anemia--chemically induced<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease Progression<br/>Dyspnea--chemically induced<br/>Everolimus<br/>Fatigue--chemically induced<br/>Female<br/>Humans<br/>Hyperglycemia--chemically induced<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Pneumonia--chemically induced<br/>Sirolimus--adverse effects<br/>Stomatitis--chemically induced<br/>Time Factors<br/>Treatment Outcome